<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> Doses First Patient in International Phase 1 Trial of Pembrolizumab Biosimilar HLX17 for Solid Tumours
Shanghai Henlius Biotech Inc. has announced the initiation of an international multi-center phase 1 clinical trial for HLX17, a biosimilar of pembrolizumab (recombinant humanised anti-PD-1 monoclonal antibody injection), in patients with multiple resected solid tumors in mainland China. The study is designed as a randomized, double-blind, parallel-controlled trial to evaluate the similarity of pharmacokinetic profiles, efficacy, safety, and immunogenicity between HLX17 and US-sourced KEYTRUDA® in patients with conditions such as non-small cell lung cancer, melanoma, or renal cell carcinoma. The trial is currently underway, with the first patient already dosed, and results have not yet been presented. The company also plans to extend the clinical trial to the United States, Europe, Australia, and other regions when conditions allow. According to IQVIA MIDAS, global sales of pembrolizumab in 2024 reached approximately USD 32.056 billion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.